ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "treatment and DMARDs"

  • Abstract Number: 538 • 2019 ACR/ARP Annual Meeting

    Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks

    Gerd Burmester1, Filip Van den Bosch 2, Louis Bessette 3, Alan Kivitz 4, Yihan Li 5, Alan Friedman 6, Aileen Pangan 6, Heidi Camp 5 and Joel Kremer 7, 1Charité—University Medicine Berlin, Berlin, Germany, 2Ghent University Hospital, Ghent, Belgium, 3Laval University, Quebec City, QC, Canada, 4Altoona Center for Clinical Research, Duncansville, PA, 5AbbVie Inc., North Chicago, IL, 6AbbVie Inc., North Chicago, 7Albany Medical College, Albany, NY

    Background/Purpose: Upadacitinib (UPA), an oral, JAK1-selective inhibitor showed efficacy over 12 weeks (wks) in patients (pts) with moderately to severely active rheumatoid arthritis (RA) and…
  • Abstract Number: 1355 • 2019 ACR/ARP Annual Meeting

    A Comparison of Clinical Improvement Following a Major Therapeutic Change Utilizing Updated Treatment Thresholds Defined by Three Different Disease Activity Measures

    Grant Cannon1, Wei Chen 1, JIncheng Shen 2, Neil Accortt 3, David Collier 4 and Brian Sauer 1, 1Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, 2Univeristy of Utah, Salt Lake City, UT, 3Amgen, Thousand Oaks, CA, 4Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Despite ACR recommendations to initiate a major therapeutic change (MTC) in rheumatoid arthritis (RA) patients with moderate/severe disease activity, our recent work has shown…
  • Abstract Number: 2340 • 2019 ACR/ARP Annual Meeting

    Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis

    Takeshi Shoda1, Tohru Takeuchi 2, Takuya Kotani 2, Koji Nagai 2, Kennichiro Hata 2, Shigeki Makino 2 and Shigeki Arawaka 2, 1Yodogawa christian hospital / Osaka medical college, Osaka, Japan, 2Osaka medical college, Osaka, Japan

    Background/Purpose: Interstitial lung disease (ILD) complicated with rheumatoid arthritis (RA) is detected in 27 to 67% of patients on high-resolution computed tomography (HRCT), and airway…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.